补肾填精方联合西药治疗再生障碍性贫血血小板影响因素的预测研究

目的：观察补肾填精方联合西药治疗再生障碍性贫血（AA）对血小板（PLT）的影响,分析影响PLT的临床因素特征。方法：选取2018年9月至2021年3月中国中医科学院西苑医院、广安门医院等19个分中心的AA患者79例作为研究对象,以补肾填精方联合西药基础治疗,连用3个月为1个疗程,连续服用2个疗程,观察患者PLT变化情况,分析PLT较基线值增长且恢复正常、较基线值增长未恢复正常的AA患者的临床因素特征。结果：AA患者接受补肾填精方联合西药治疗4个月后,PLT较基线值增长且恢复正常的有13例,PLT较基线值增长未恢复正常的有66例。对一般资料分析显示,中医证候积分越低,补肾填精方联合西药治疗,PLT越容易恢复正常（P<0.05）。对治疗前血常规分析结果显示,治疗前血红蛋白≥60 g/L时、中性粒细胞数值越高时、网织红细胞比率＜0.5%时,补肾填精方联合西药治疗,PLT越容易恢复正常（P<0.05）。对治疗前T淋巴细胞亚群结果分析显示,CD3+CD19-＜60%时,以补肾填精方联合西药治疗,PLT更容易恢复正常（P<0.05）。结论：当AA患者的中医证候积分越低、血红蛋白≥60 g/L、中性粒细胞数值越高、网织红细胞比率＜0.5%、CD3+CD19-＜60%且越低时,以补肾填精方联合西药治疗,AA患者的PLT更容易增加并恢复正常（P<0.05）。     

白血病抑制因子基因在急性白血病患者中的表达及意义

目的研究急性白血病(acute leukemia,AL)患者外周血白血病抑制因子(leukemia inhibitory factor,LIF)mRNA的表达水平及其与AL病情、疗效和预后的关系。方法采用逆转录聚合酶链反应(RT-PCR)检测37例不同类型以及同一类型不同阶段AL患者[初治患者16例(初治亚组)、完全缓解患者12例(完全缓解亚组)、复发患者9例(复发亚组)]LIF的mRNA的表达水平,并与20例健康者(对照组)比较。结果初治亚组LIF基因mRNA阳性表达率低于对照组和完全缓解亚组(P<0.05);复发亚组LIF基因mRNA阳性表达率低于完全缓解组(P<0.05);复发亚组与初治亚组比较及完全缓解亚组与对照组比较,LIF基因mRNA阳性表达率差异无统计学意义(P>0.05);LIF基因表达率在急性髓系白血病(AML)和急性淋巴细胞白血病(ALL)患者间无显著性差异(P>0.05)。结论 LIF基因表达水平与AL患者病情变化密切相关。检测AL患者LIF基因表达情况,为AL患者检测病情、疗效评价、指导临床用药和预后判断,提供了一定的理论依据。     

伴NPM1基因突变的成年人急性髓系白血病临床研究

Objective To evaluate the clinical feature of adult acute myeloid leukemia with nucleophosmin (NPM1) cytoplastic positive (NPMc+AML), and to investigate the significance of the NPM1 gene mutations regularly in detecting the early relapse. Methods The NPM1 gene mutations was screened by the PCR-capillary electrophoresis in 95 newly diagnosed adult AML patients. 5 complete remission AML patients were selected to detecte the NPM1 gene mutations regularly. Results In 95 cases of adult AML patients, the incidence of the NPM1 mutations was 9.5 % (28/95). The incidence of the NPM1 mutations in patients (≥40-year-old) was higher clearly than it' s in pazients (40-year-old) (λ 2= 6.963, P = 0.012). That in the AML patients with normal karyotype (51.1%) was higher than that in the patients with abnormal karyotype (8.3 %) (λ2= 20.860, P= 0.0000). NPM1 mutations occured with a considerate percentage in AML patients with M5/M2 subtype. In AML with recurrent genetic abnormalities the NPM1 mutations wasn' t found.The white blood cell count, platelet count, lactate dehydrogenase in the NPMc+AML patients were clearly higher than that in the NPMc-AML patients (t were individually 4.132, 4.603, 4.069, P ＜0.05). The rate of complete remission, relapse-free survival and overall survival in the NPMc+AML patients were also higher than that in the N PMc-AML patients (λ 2 were individually 10.448, 4.146, 4.384, P ＜0.05). In cases detected regularly NPM1 mutations preceded the hematological relapse about 1.5-2 months. Conclusion NPM1 gene mutations has a higher incidence in adult AML, particularly in normal karyotype AML. The clinical manifestations are older, and higher in white blood cell count, platelet count, and lactate dehydrogenase. The NPM1 mutations in adult AML is a good factor for prognosis. The regular detection of NPM1 mutation could find relapse early.     

骨髓增生异常综合征患者Fas和FasL蛋白的表达及对造血祖细胞的影响

目的　探讨骨髓增生异常综合征 (MDS)患者骨髓细胞Fas(CD95 )及其配体 (FasL)的蛋白表达和作用。方法　采用免疫组化方法检测患者和正常对照组骨髓细胞Fas和FasL的表达。体外培养观察Fas免疫球蛋白(Fas Ig)及TNFα抗体对患者造血祖细胞集落形成的影响 ,酶联免疫吸附试验测定培养细胞的胞质DNA片段以观察凋亡情况。结果　①MDS患者 77% (2 0 / 2 6例 )表达Fas蛋白 ,81% (2 1/ 2 6例 )表达FasL蛋白 ,正常对照组无表达。②Fas、FasL表达与FAB分型有关 :Fas蛋白表达 ,难治性贫血 (RA)显著高于RA伴有原始细胞过多(RAEB)者、转变中的RAEB(RAEB t)和继发于MDS的急性髓细胞白血病 (postMDS AML) (RA >RAEB >RAEB -t >postMDS -AML) ,但RA患者的FasL表达最低。③体外培养发现 ,加入Fas Ig或TNFα抗体以阻断其途径 ,MDS患者粒细胞 巨噬细胞集落生成单位 (CFU GM)和红细胞集落生成单位 (CFU E)的集落形成显著增加 ,培养细胞的胞质DNA片段显著下降。结论　MDS骨髓细胞Fas和FasL的表达异常 ,并具功能活性。Fas、FasL可能是MDS凋亡机制之一     

幽门螺杆菌在儿童特发性血小板减少性紫癜中的临床意义

本研究旨在探讨幽门螺杆菌(helicobacter pylori,HP)在儿童特发性血小板减少性紫癜(ITP)中的临床意义。用13C尿素呼气试验检测92例ITP儿童患者的感染情况,并检测66名健康儿童作为对照组。将ITP患儿中68例阳性者随机分为2组:复合用药治疗组34例,应用糖皮质激素+抗菌治疗;单药治疗组34例,用糖皮质激素治疗。结果表明:ITP患儿HP的感染率为74.7%,明显高于对照组(39.4%)(P<0.05)。ITP患儿经治疗后,单药治疗组的总有效率(73.5%)明显低于复合用药治疗组的总有效率(94.1%)(P<0.05);治疗组1年内的复发率(17.6%)明显低于单药治疗组(47.1%)(P<0.05);治疗过程中患儿外周血血小板计数均呈逐渐上升趋势,在相同时间点,复合用药治疗组血小板计数明显高于单药治疗组(P<0.01)。结论:ITP患儿HP感染率高于健康儿童,HP可能参与了儿童ITP的发病过程,抗HP治疗可提高ITP患儿的治疗效果,降低其复发率。     

伴NPM1基因突变的成年人急性髓系白血病临床研究

Objective To evaluate the clinical feature of adult acute myeloid leukemia with nucleophosmin (NPM1) cytoplastic positive (NPMc+AML), and to investigate the significance of the NPM1 gene mutations regularly in detecting the early relapse. Methods The NPM1 gene mutations was screened by the PCR-capillary electrophoresis in 95 newly diagnosed adult AML patients. 5 complete remission AML patients were selected to detecte the NPM1 gene mutations regularly. Results In 95 cases of adult AML patients, the incidence of the NPM1 mutations was 9.5 % (28/95). The incidence of the NPM1 mutations in patients (≥40-year-old) was higher clearly than it' s in pazients (40-year-old) (λ 2= 6.963, P = 0.012). That in the AML patients with normal karyotype (51.1%) was higher than that in the patients with abnormal karyotype (8.3 %) (λ2= 20.860, P= 0.0000). NPM1 mutations occured with a considerate percentage in AML patients with M5/M2 subtype. In AML with recurrent genetic abnormalities the NPM1 mutations wasn' t found.The white blood cell count, platelet count, lactate dehydrogenase in the NPMc+AML patients were clearly higher than that in the NPMc-AML patients (t were individually 4.132, 4.603, 4.069, P ＜0.05). The rate of complete remission, relapse-free survival and overall survival in the NPMc+AML patients were also higher than that in the N PMc-AML patients (λ 2 were individually 10.448, 4.146, 4.384, P ＜0.05). In cases detected regularly NPM1 mutations preceded the hematological relapse about 1.5-2 months. Conclusion NPM1 gene mutations has a higher incidence in adult AML, particularly in normal karyotype AML. The clinical manifestations are older, and higher in white blood cell count, platelet count, and lactate dehydrogenase. The NPM1 mutations in adult AML is a good factor for prognosis. The regular detection of NPM1 mutation could find relapse early.     

CD20在多发性骨髓瘤中的表达特点及临床意义

目的 探讨CD20在多发性骨髓瘤(MM)患者中的表达特点及临床意义.方法 选取2010年6月至2016年6月于潍坊市人民医院及潍坊医学院附属医院初诊的MM患者197例为研究对象,回顾性分析其实验室结果及临床资料.结果 197例MM患者中检出CD20表达阳性者41例(20.8％),CD20表达阴性者156例(79.2％);CD20阳性组患者中检出CD56表达阳性率明显低于CD20阴性组(P＜0.05),其余免疫表型:CD38、CD13、CD33、CD117、CD138、CD19、CD45在两组中表达差异均无统计学意义(P＞0.05);CD20阳性组骨髓中检出瘤细胞比例高于CD20阴性组(P＜0.05),静脉血血红蛋白含量低于CD20阴性组(P＜0.05),髓外浸润率低于CD20阴性组(P＜0.05),两组患者的年龄、性别、血小板、肾功能损害、LDH、免疫球蛋白类型、D-S分期、ISS分期差异均无统计学意义(P＞0.05).结论 CD20阳性患者表达CD56阳性率低,更倾向于骨髓内增殖、累及红系造血而非髓外浸润.     

骨髓增生异常综合征骨髓细胞凋亡的研究

目的研究骨髓增生异常综合征(MDS)患者骨髓细胞凋亡改变,以探讨MDS疾病本质。方法采用TUNEL法检测42例MDS、11例巨幼细胞贫血(MegA)、8例阵发性睡眠性血红蛋白尿症(PNH)、6例Evans综合征患者和10例正常健康对照组的新鲜骨髓单个核细胞(BMMNC)的凋亡情况。结果23例(54.8%)MDS患者BMMNC呈现凋亡过度,而MegA、PNH、Evans综合征患者与对照组比较无显著差异;且MDS患者凋亡累及粒、红、巨三系各阶段造血细胞,随病情进展,凋亡程度逐渐下降。结论MDS患者存在骨髓细胞过度凋亡,凋亡过度可能为导致MDS无效造血的机制之一,病情进展可能与异常克隆逃逸凋亡有关,抗凋亡治疗为早期MDS治疗提供了新思路。     

急性白血病自体骨髓移植患者应用rhGM—CSF的临床观察

为探讨重组人粒-巨噬细胞集落刺激因子(rhGM-CSF)在自体骨髓移植(ABMT)中的临床价值,将18例进行ABMT的急性白血病患者随机分成2组,受试组9例,自预处理后第7天开始应用rhGM-CSF,每日300μg持续静脉滴注,连用14d;另选9例为对照组.结果显示,外周血中性粒细胞绝对值(ANC)达0.5X10~9/L的时间,受试组为15d,对照组26d(P相似文献   

DWI评估N-乙酰-5-羟色胺对脑缺血再灌注大鼠脑水肿的影响

目的 采用DWI观察N-乙酰-5-羟色胺（NAS）对急性局灶性脑缺血再灌注（IR）大鼠脑水肿的神经保护作用。方法 将66只大鼠随机分为假手术组（n=10）、大脑中动脉阻塞（MCAO）组（n=28）和NAS组（n=28）。对MCAO组和NAS组大鼠IR后6 h、24 h、72 h、7天,对假手术组于72 h,分别行DWI和病理学检查,比较3组不同时间点脑梗死区相对ADC值（rADC）、相对指数ADC值（reADC）、水通道蛋白4（AQP4）阳性细胞数的变化。IR后72 h,测量各组脑组织含水量的变化。结果 假手术组大鼠MRI检测未见异常信号。NAS组与MCAO组大鼠DWI图均可见损伤侧大脑皮层及纹状体异常高信号,ADC图为低信号,eADC图为高信号。IR后6、24、72 h,NAS组rADC值均高于MCAO组（P均<0.05）,reADC值和AQP4阳性细胞数低于MCAO组（P均<0.05）;IR后7天,各组rADC值、reADC值及AQP4阳性细胞数差异无统计学意义（P均>0.05）。IR后72 h,NAS组大鼠脑组织水含量低于MCAO组（P<0.05）。结论 NAS可减轻急性IR脑损伤大鼠脑水肿,其机制可能与下调AQP4蛋白的表达有关;DWI对评价NAS的神经保护作用具有重要价值。